ADMA Biologics Inc (ADMA)
17.40
-0.50
(-2.79%)
USD |
NASDAQ |
Dec 20, 16:00
17.47
+0.07
(+0.40%)
After-Hours: 20:00
ADMA Biologics PE Ratio: 62.14 for Dec. 20, 2024
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Corcept Therapeutics Inc | 40.82 |
| Alnylam Pharmaceuticals Inc | -- |
| Catalyst Pharmaceuticals Inc | 18.03 |
| Sarepta Therapeutics Inc | 77.25 |
| Krystal Biotech Inc | 92.56 |
PE Ratio Related Metrics
| PS Ratio | 10.79 |
| Price to Book Value | 17.74 |
| Price to Free Cash Flow | 52.39 |
| Price | 17.40 |
| Earnings Yield | 1.61% |
| Market Cap | 4.113B |
| Operating PE Ratio | 35.94 |
| Normalized PE Ratio | 62.14 |